A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival

Baecklund, Fredrik; Foo, Jia-Nee; Bracci, Paige; Darabi, Hatef; Karlsson, Robert; Hjalgrim, Henrik; Rosenquist, Richard; Adami, Hans-Olov; Glimelius, Bengt; Melbye, Mads; Conde, Lucia; Liu, Jianjun; Humphreys, Keith; Skibola, Christine F; Smedby, Karin E

doi:10.1186/s12881-014-0113-6

BMC Medical Genetics

Table 1 List of single nucleotide polymorphisms (SNPs) associated with follicular lymphoma outcome (p < 0.05) in at least one previously published study, and results for these variants in other previous studies

From: A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival

Chr	Gene	SNP	Minor/major allele	Study	# FL cases	# SNPs tested	Outcome	Relative risk ratio	# Studies reporting no association [refs]
1	C1qA	rs172378	A/G	Racilia 2008	133	3	PFS	2.5 (2.0, 3.1)	none
1	CD46	rs2466571	C/A	Charbonneau 2012	107	167	EFS	1.49 (0.86, 2.61), p_trend < 0.05	none
1	CD55	rs2564978	T/C	Charbonneau 2012	107	167	EFS	0.52 (0.30, 0.88)	none
1	CFH	rs1065489	T/G	Charbonneau 2012	107	167	EFS	0.44 (0.24, 0.81)	none
1	CFH	rs1329423	C/T	Charbonneau 2012	107	167	EFS	0.49 (0.29, 0.82)	none
1	CFH	rs3766404	G/A	Charbonneau 2012	107	167	EFS	2.25 (1.31, 3.87)	none
1	CFHR1	rs436719^A	C/A	Charbonneau 2012	107	167	EFS	0.57 (0.34, 0.96)	none
1	CFHR5	rs6694672	G/T	Charbonneau 2012	107	167	EFS	2.63 (1.41, 4.92)	none
1	FCGR2A	rs1801274	A/G	Weng 2003	87	2	PFS	Decreased rate, p_log-rank < 0.02	4 [10],[13],[14],[16]
			A/G	Cerhan 2007	278	73	OS	0.58 (0.31, 1.04), p_trend = 0.04	2 [10],[13]
1	FCGR3A	rs396991^A	G/T	Weng 2003	87	2	PFS	Decreased rate, p_log-rank < 0.03	5 [6],[10],[13],[14],[16]
			G/T	Ghielmini 2005	185	1	EFS	0.5 (0.3, 0.9)	1 [5]
			G/T	Persky 2012	142	2	OS	0.33 (0.11; 0.96)	1 [10]
			G/T	Cartron 2002	49	2	RR	1.5 (1.2, 1.9)	1 [10]
1	MTHFR	rs1801131	C/A	Wang 2009	192	66	OS	2.00 (1.04, 3.84)	none
1	SELE	rs5361		Aschenbrook- Kilfoy 2012	117	82	OS	0.10 (0.02, 0.48)	1 [7]
2	IL1RN	rs454078	T/A	Cerhan 2007	278	73	OS	0.50 (0.28, 0.87)	1 [3]
3	CCR2	rs1799864^A		Aschenbrook- Kilfoy 2012	117	82	OS	0.27 (0.08, 0.86)	1 [7]
3	FTHFD	rs1127717	G/A	Wang 2009	192	66	OS	1.99 (1.07, 3.7)	none
4	IL2	rs2069762	G/T	Cerhan 2007	278	73	OS	1.81 (1.06, 3.07)	none
4	IL8	rs4073	T/A	Aschenbrook- Kilfoy 2012	117	82	OS	2.60 (1.10, 6.15)	none
			A/T	Cerhan 2007	278	73	OS	0.47 (0.27, 0.79), p_trend = 0.06	none
4	IL8	rs2227307	T/G	Aschenbrook- Kilfoy 2012	117	82	OS	2.57 (1.07, 6.17)	none
			G/T	Cerhan 2007	278	73	OS	0.53 (0.31, 0.91), p_trend = 0.11	none
4	IRF2	rs3775567^A	T/	Gibson 2012^A	244	6679	OS	3.18 (1.72, 5.87)	none
5	C9	rs1421094	A/G	Charbonneau 2012	107	167	EFS	0.54 (0.32, 0.90)	none
5	IL12B	rs3212227	C/A	Cerhan 2007	278	73	OS	2.01 (1.18, 3.42)	none
6	C6orf15	rs6457327	A/C	Wrench 2011	218	2	TTT	2.25. (1.16, 4.36)	none
				Berglund 2011	102	1	OS	Increased rate, p = 0.006	none
6	IFNGR1	rs3799488		Aschenbrook- Kilfoy 2012	117	82	OS	3.19 (1.09, 9.34)	1 [7]
8	GGH	rs719235	T/G	Wang 2009	192	66	OS	2.49 (1.21, 5.14)	none
9	GALNT12	rs10987898^A	G/	Gibson 2012^A	244	6679	OS	0.48 (0.27, 0.83)	none
9	GALNT12	rs10819377	T/	Gibson 2012^A	244	6679	OS	0.62 (0.36, 1.03), p_trend < 0.001	none
11	CXCR5	rs1790192	G/A	Charbonneau 2013^A	172	10	EFS	0.64 (0.47; 0.87)	none
16	IL4R	rs1801275		Aschenbrook- Kilfoy 2012	117	82	OS	2.35 (1.07, 5.19)	none
20	BMP7	rs6025446^A	G/A	Gibson 2012^A	244	6679	OS	0.41 (0.21, 0.69)	none
22	MIF	rs755622		Aschenbrook- Kilfoy 2012	117	82	OS	2.45 (1.09,5.47)	none

EFS = event-free survival, PFS = progression-free survival, OS = overall survival, TTT = time to transformation, RR = response to Rituximab. R = Rituximab, KM = Kaplan-Meier curve. ^AVariant was not available for evaluation in the present study.

Back to article page

ISSN: 1471-2350

Contact us

General enquiries: ORSupport@springernature.com